Opus Genetics, Inc. (IRD)
(Delayed Data from NSDQ)
$1.07 USD
-0.04 (-3.60%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.09 +0.02 (1.87%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IRD 1.07 -0.04(-3.60%)
Will IRD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IRD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRD
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates
IRD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Other News for IRD
Opus Genetics (IRD) Partners with Global RDH12 Alliance for Gene Therapy Advancement | IRD ...
Opus Genetics (IRD) Forms Strategic Partnership to Advance Gene Therapy | IRD Stock News
Opus Genetics, Global RDH12 Alliance partner to advance RDH12 gene therapy
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | IRD Stock News